2019 Clinical Trials DEA Programs 
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 9, 2021
Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
Cannabis Law Report
DECEMBER 21, 2021
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).
Cannabis Law Report
MARCH 2, 2020
In March 2019, J&J’s hard work paid off when the FDA approved Spravato for treatment-resistant depression. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Fortunately, this issue shouldn’t be a show-stopper. Potential IPOs within the next year.
SpeedWeed
MARCH 5, 2021
One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.
Veriheal
JUNE 29, 2021
The Right to Try Act or the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act was signed into law on May 30th, 2019, according to the US Food and Drug Administration. The FDA refers to this program as the expanded access program on their website.
Expert insights. Personalized for you.
52 
Let's personalize your content